A new treatment approach to improve outcomes for patients with earlier stages of gastric and gastroesophageal junction cancers has had positive high-level results from a planned interim analysis of a phase 3 trial.
By Charm Therapeutics gains investment from NVentures for cancer therapeutics
Charm Therapeutics has announced investment from NVentures – NVIDIA’s venture investment arm. This represents a major milestone for Charm and means it will be able to deliver more on its research and development (R&D) activities for novel oncology...
Redx has been presented with a commemorative plaque at its HQ at Alderley Park, in recognition of its discovery of pirtobrutinib, the active pharmaceutical ingredient (API) in Eli Lilly's cancer treatment Jaypirca.
Results from a multinational trial of trifluridine/tipracil, known as Lonsurf, with or without bevacizumab in refractory metastatic colorectal cancer (mCRC) have resulted in statistically significantly and clinically meaningful improvements.
Scorpion Therapeutics, a clinical-stage oncology company, has announced that the first patient has been dosed in a phase 1/2 clinical trial of STX-478, its treatment for breast cancer and other solid tumors.
A breakthrough in rectal cancer treatment has been discovered through a collaboration between a cancer intelligence company and the world’s largest and oldest cancer center. It could put an end to the invasive surgery patients may have faced.
The clinical stage biopharmaceutical company will use its RADR artificial intelligence (AI) and machine learning platform to transform the cost, pace, and timeline of oncology drug discovery and development.
After a successful evaluation of its whole-genome sequencing-based test for solid tumor minimal residual disease (MRD) C2i Genomics announced today (January 5) that they have extended their collaboration with AstraZeneca.